Results 1 to 10 of about 2,707 (157)

Delamanid-containing regimens over 24 weeks for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis: preliminary results from a single center in a multicenter, prospective, observational study [PDF]

Frontiers in Medicine
BackgroundSingle center preliminary results from a multicenter, prospective, observational study whose aims were to investigate the efficacy and safety of 24-week delamanid-containing regimens in Chinese multidrug-resistant/rifampicin-resistant ...
Fuping Yang, Mingdan Yin, Xingmei Jiang, Xing Zhao, Xuemei An, Yan Liu, Yijia Yuan   +6 more
doaj   +2 more sources

Delamanid: Safety and Efficacy Analysis

Туберкулез и болезни лёгких, 2023
The review presents the analysis of 50 publications describing treatment of multiple drug resistant tuberculosis with regimens containing the new drug of delamanid.
G. N. Mozhokina, A. G. Samoylova, I. A. Vasilyeva, A. V. Abramchenko   +3 more
doaj   +2 more sources

A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial [PDF]

Signal Transduction and Targeted Therapy
Tuberculosis (TB) is a contagious disease that threatens human health worldwide. Combination chemotherapy is usually recommended for this disease. Recently, 2 nitroimidazole-based agents, namely, delamanid and pretomanid, have been approved by regulatory
Naihui Chu, Wenjuan Nie, Juan Du, Manni Wang, Liping Ma, Qingfeng Wang, Jun Wang, Xiaomeng Hu, Jin Wu, Yu Lu, Mailing Huang, Yuquan Wei, Zhenling Wang, Jian-Qing He, Zhenyu Ding, Xiawei Wei   +15 more
doaj   +2 more sources

Safety and outcome of bedaquiline and delamanid-based longer oral regimen in Indian children less than 5 years with drug-resistant tuberculosis [PDF]

Lung India
Background: Paediatric drug-resistant tuberculosis (DR-TB) remains a significant challenge, especially in high-burden countries like India. While bedaquiline (BDQ) and delamanid (DLM) are shown to be successful in treating multi-drug-resistant TB (MDR-TB)
Ira Shah, Ramsha Ansari, Dhruv N. Gandhi, Suhani Jain, Varsha Puri, Daksha Shah, Sanjay K. Mattoo, Minnie Bodhanwala   +7 more
doaj   +2 more sources

Global child-friendly anti-TB medicines – where do we stand? [PDF]

IJTLD Open
SUMMARY: An increasing number of children are diagnosed and started on antituberculosis treatment. Despite progress in developing child-friendly antituberculosis formulations for drug-susceptible and drug-resistant TB, a single-medicine rifampicin ...
H.S. Schaaf, D.T. Wademan, L.E. van der Laan   +2 more
doaj   +2 more sources

Delamanid is a new anti-tuberculosis drug: use, limitations, and prospects

Туберкулез и болезни лёгких, 2021
The review analyses 61 publications on the use of delamanid, a new drug for the treatment of drug resistant tuberculosis. It presents information about pharmacokinetic parameters, efficacy and safety, as well as the place of delamanid in the combination ...
V. N. Zimina, I. B. Viktorova
doaj   +1 more source

Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study

Journal of Microbiology, Immunology and Infection, 2023
Background/Purpose(s): Bedaquiline and delamanid were recently approved for multidrug resistant tuberculosis (MDR-TB). Bedaquiline carries a black box warning of increased risk of death compared to the placebo arm, and there is a need to establish the ...
Ju Hwan Kim, Hyesung Lee, In-Sun Oh, Han Eol Jeong, Sungho Bea, Seung Hun Jang, Hyunjin Son, Ju-Young Shin   +7 more
doaj   +1 more source

Delamanid or pretomanid? A Solomonic judgement! [PDF]

Journal of Antimicrobial Chemotherapy, 2022
Abstract Given the low treatment success rates of drug-resistant tuberculosis (TB), novel TB drugs are urgently needed. The landscape of TB treatment has changed considerably over the last decade with the approval of three new compounds: bedaquiline, delamanid and pretomanid. Of these, delamanid and pretomanid belong to the same class of
Saskia E. Mudde, Anna M. Upton, Anne Lenaerts, Hannelore I. Bax, Jurriaan E. M. De Steenwinkel   +4 more
openaire   +2 more sources

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.

PLOS Global Public Health, 2023
Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results.
Carly A Rodriguez, Sara Lodi, C Robert Horsburgh, Carole D Mitnick, Mathieu Bastard, Helena Huerga, Uzma Khan, Michael Rich, Kwonjune J Seung, Sidney Atwood, Md Manzur-Ul-Alam, Nara Melikyan, Stephanie Mpinda, Zaw Myint, Yugandran Naidoo, Ofelya Petrosyan, Naseem Salahuddin, Samreen Sarfaraz, Stalz Charles Vilbrun, Kalkidan Yae, Jay Achar, Saman Ahmed, Elena Algozhina, Jude Beauchamp, Sara de Guadelupe Perea Moreno, Munara Gulanbaeva, Marika Gergedava, Cut Yulia Indah Sari, Catherine Hewison, Palwasha Khan, Molly F Franke   +30 more
doaj   +1 more source

Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China

Journal of Global Antimicrobial Resistance, 2021
: Objectives: The new antituberculous drugs delamanid and bedaquiline form the last line of defence against drug-resistant tuberculosis (TB). Understanding the background prevalence of resistance to new drugs can help predict the lifetime of these drugs’
Wencong He, Chunfa Liu, Dongxin Liu, Aijing Ma, Yimeng Song, Ping He, Jingjing Bao, Yuanchun Li, Bing Zhao, Jiale Fan, Qian Cheng, Yanlin Zhao   +11 more
doaj   +1 more source